Tell your healthcare provider about all of your health conditions, including if you: Show
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VENTOLIN HFA and certain other medicines may interact with each other. This may cause serious side effects. Especially tell your healthcare provider if you take:
Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. Key PointsKEYPOINTS: MANAGING EXACERBATIONS OF ASTHMA
KEY DIFFERENCES FROM 1997 AND 2002 EXPERTPANEL REPORTS
IntroductionIn this section, recommendations are presented for the assessment and treatment of exacerbations in the home, ED, and hospital. See section 1, "Overall Methods Used To Develop This Report," for literature search strategy and tally of results for this EPR—3: Full Report 2007 section on "Managing Exacerbations of Asthma." Four Evidence Tables were prepared: 17, Increasing the Dose of Inhaled Corticosteroids; 18, IV Aminophylline; 19, Magnesium Sulfate; and 20, Heliox. Asthma exacerbations are acute or subacute episodes of progressively worsening shortness of breath, cough, wheezing, and chest tightness—or some combination of these symptoms. Exacerbations are characterized by decreases in expiratory airflow that can be documented and quantified by simple measurement of lung function (spirometry or PEF). These objective measures more reliably indicate the severity of an exacerbation than does the severity of symptoms. In general, milder exacerbations may be managed "at home" (i.e., outside the health care system), whereas more serious exacerbations may require an unscheduled ("urgent") office visit, an ED visit, or a hospital admission (see figure 5-1). The most severe exacerbations require admission to the intensive care unit (ICU) for optimal monitoring and treatment. Although assessment and treatment of young children pose unique challenges, the management of asthma exacerbations in older children and adults is fairly similar. Figure 5-1CLASSIFYING SEVERITY OF ASTHMA EXACERBATIONS IN THE URGENT OR EMERGENCY CARE SETTING Individuals who have their asthma under control with ICSs will decrease the risk of exacerbations. Nonetheless, patients in good control can still be vulnerable to exacerbations, for example, when they have clinical respiratory infections (Reddel et al. 1999). Diurnal variability, a marker of poor control, may not change during an exacerbation; thus, clinicians may fail to detect important changes in lung function. The striking difference between PEF variations during exacerbations, as compared with during poor asthma control, suggests differences in beta2-adrenoceptor function between these conditions. The decrease in responsiveness to SABA during some severe exacerbations may help to explain the benefit of ipratropium bromide and other "alternative" approaches to bronchodilation. General ConsiderationsBased on the scientific literature and the opinion of the Expert Panel, the Panel recommends that clinicians consider the following general principles and goals for managing asthma exacerbations: early treatment, special attention to patients who are at high risk of asthma-related death, and special attention to infants (EPR—2 1997).
Figure 5-2aRISK FACTORS FOR DEATH FROM ASTHMA Sources: Abramson et al. 2001; Greenberger et al. 1993; Hardie et al. 2002; Kallenbach et al. 1993; Kikuchi et al. 1994; O'Hollaren et al. 1991; Rodrigo and Rodrigo 1993; Strunk and Mrazek 1986; Suissa et al. 1994 Figure 5-2bSPECIAL CONSIDERATIONS FOR INFANTS Source: EPR—2 1997. Treatment GoalsThe principal goals and Expert Panel recommendations for treating asthma exacerbations are:
Figure 5-3FORMAL EVALUATION OF ASTHMA EXACERBATION SEVERITY IN THE URGENT OR EMERGENCY CARE SETTING Notes: Home Management of Asthma ExacerbationsBeginning treatment at home avoids treatment delays, prevents exacerbations from becoming severe, and also adds to patients' sense of control over their asthma. The degree of care provided in the home depends on the patients' (or parents') abilities and experience and on the availability of emergency care. General guidelines for managing exacerbations at home are presented in figure 5-4. Figure 5-4MANAGEMENT OF ASTHMA EXACERBATIONS: HOME TREATMENT The Expert Panel recommends preparing patients for home management of asthma exacerbations by taking the following actions (Also see "Component 1: Measures of Asthma Assessment and Monitoring," and "Component 2: Education for a Partnership in Asthma Care.").
The Expert Panel recommends the following pharmacologic therapy for home management of exacerbations:
The Expert Panel does not recommend the following home management techniques, because no studies have demonstrated effectiveness, and it is the opinion of the Panel that these techniques may delay patients from obtaining necessary care (EPR—2 1997).
The Expert Panel also notes that although pursed-lip and other forms of controlled breathing may help to maintain calm during respiratory distress, these methods do not bring about improvement in lung function. Prehospital Management of Asthma ExacerbationsThe Expert Panel recommends that emergency medical services (EMS) providers administer supplemental oxygen and SABA to patients who have signs or symptoms of an asthma exacerbation (Evidence A). Prehospital administration of SABA reduces airflow obstruction and relieves symptoms (Fergusson et al. 1995; Markenson et al. 2004; Richmond et al. 2005). Ideally, all EMS providers would receive a standing order to allow them to provide albuterol to their patients who have asthma exacerbations. Such an order would be consistent with their legally authorized scope of practice and local medical direction (Camargo 2006). In such settings, EMS providers should have available a nebulizer and/or an inhaler plus spacer/holding chamber for SABA administration (see figure 5-5 for dosages). If these are not available, subcutaneous epinephrine or terbutaline should be given for severe exacerbations (See figure 5-5.) (Sly et al. 1977; Smith et al. 1977). Figure 5-5DOSAGES OF DRUGS FOR ASTHMA EXACERBATIONS Notes: When initiating bronchodilatory use, EMS personnel should not delay transport of the patient to the appropriate medical facility. The treatment, however, may be repeated while transporting the patient. Prolonged transport times (e.g., in a rural setting or during transport on congested urban streets) may necessitate multiple inhaled SABA treatments before arrival at the medical facility (Crago et al. 1998). Patients should receive a maximum of three inhaled SABA treatments in the first hour, and then one per hour thereafter (consistent with practice in the ED setting; see figures 5-5 and 5-6). After each treatment, EMS personnel should reassess and record the patient's vital signs and lung sounds. Figure 5-6MANAGEMENT OF ASTHMA EXACERBATIONS: EMERGENCY DEPARTMENT AND HOSPITAL-BASED CARE Ambulance services should develop prehospital protocols for the treatment of acute asthma in children and adults (Markenson et al. 2004; Stead and Whiteside 1999). With medical oversight, these protocols can allow for more frequent administration of several established acute asthma treatments, such as ipratropium bromide and oral systemic corticosteroids (Knapp and Wood 2003). The latter medication is particularly important during prolonged transport times. All prehospital providers should receive training in how to respond to the clinical signs and symptoms of severe airway obstruction and imminent respiratory failure (Camargo 2006). Emergency Department and Hospital Management of Asthma ExacerbationsSevere exacerbations of asthma are potentially life threatening. Care must be prompt. Effective initial therapies (i.e., SABA and the means of giving it by aerosol and a source of supplemental oxygen) should be available in a physician's office. Serious exacerbations, however, require close observation for deterioration, frequent treatment, and repetitive measurement of lung function. Therefore, most severe exacerbations of asthma require prompt transfer to an ED for more complete therapy (McFadden 2003; Rowe et al. 2001). Despite appropriate therapy, approximately 10–25 percent of ED patients who have acute asthma will require hospitalization (Pollack et al. 2002; Weber et al. 2002). In the hospital, multidisciplinary (e.g., nursing and respiratory care) clinical pathways for asthma appear to be effective in reducing hospital length-of-stay and inpatient costs, but they have less clear impact on clinical outcomes (Banasiak and Meadows-Oliver 2004). An overview of the treatment strategies in EDs and hospitals is presented in figure 5-6 and detailed below. ASSESSMENTThe Expert Panel recommends the following activities to assess exacerbations:
TREATMENTThe Expert Panel recommends as initial treatments: oxygen for most patients, SABA for all patients; adding multiple doses of ipratropium bromide for ED patients who have severe exacerbations (but ipratropium bromide is not recommended during hospitalization); and systemic corticosteroids for most patients. For severe exacerbations unresponsive to the initial treatments, adjunct treatments (magnesium sulfate or heliox) merit consideration to decrease the likelihood of intubation. (See the following discussion for evidence levels.) The Expert Panel does not recommend: methylxanthines, antibiotics (except as needed for comorbid conditions), aggressive hydration, chest physical therapy, mucolytics, or sedation. (For evidence levels, see the following discussion.) In the ED and hospital, tailor the intensity of treatment and surveillance to the severity of the exacerbation. The primary therapies—the administration of oxygen, SABA, and systemic corticosteroids—are constant, but the dose and frequency with which they are given and the frequency with which the patient's response is assessed may vary. Thus, for patients presenting with a severe exacerbation, give SABA therapy at the higher dose plus ipratropium bromide (figure 5-5) either repeatedly (three treatments in the first hour) or continuously (by nebulization) (Evidence A). Give systemic corticosteroids immediately, and watch closely for signs of worsening airflow obstruction or fatigue. For patients who have mild exacerbations, give SABA therapy and assess the patient's response before deciding whether additional therapy is necessary. When SaO2 monitoring is not available, give supplemental oxygen to patients who have significant hypoxemia and to patients who have FEV1 or PEF <40 percent of predicted. The Expert Panel recommends the following treatments:
The following treatments are NOT recommended:
REPEAT ASSESSMENTThe Expert Panel recommends that repeat assessment of patients who have severe exacerbations be made after the initial dose of a SABA and that repeat assessment of all patients be made after three doses of a SABA (60–90 minutes after initiating treatment) (Evidence A). The response to initial treatment in the ED is a better predictor of the need for hospitalization than is the severity of an exacerbation on presentation (Cham et al. 2002; Chey et al. 1999; Gorelick et al. 2004b; Karras et al. 2000; Kelly et al. 2002b and 2004; McCarren et al. 2000; Rodrigo and Rodrigo 1993, 1998c; Smith et al. 2002). The elements to be evaluated include the patient's subjective response, physical findings, FEV1 or PEF, and measurement of pulse oximetry or ABG (if the patient meets the criteria described in the earlier discussion of laboratory studies). HOSPITALIZATIONThe Expert Panel recommends that the decision to hospitalize a patient be based on duration and severity of symptoms, severity of airflow obstruction, response to ED treatment (See earlier section on monitoring in "Treatment Goals."), course and severity of prior exacerbations, medication use at the time of the exacerbation, access to medical care and medications, adequacy of support and home conditions, and presence of psychiatric illness (Evidence C) (Pollack et al. 2002; Weber et al. 2002.). In general, the principles of care in the hospital and recommendation for treatment resemble those for care in the ED and involve both treatment (with oxygen, aerosolized SABA, and systemic corticosteroids and, perhaps, adjunct therapies) and frequent assessment, including clinical assessment of respiratory distress and fatigue as well as objective measurement of airflow (PEF or FEV 1 ) and oxygen saturation (EPR—2 1997). IMPENDING RESPIRATORY FAILUREThe Expert Panel recommends that intubation not be delayed once it is deemed necessary; exactly when to intubate is based on clinical judgment (Evidence D). Most patients respond well to therapy. However, a small minority will show signs of worsening ventilation, whether from worsening airflow obstruction, worsening respiratory muscle fatigue, or a combination of the two. Signs of impending respiratory failure include inability to speak, altered mental status, intercostal retraction (Cham et al. 2002), worsening fatigue, and a PCO2 of ≥42 mmHg. Because respiratory failure can progress rapidly and can be difficult to reverse, early recognition and treatment are critically important. The Expert Panel recommends that adjunct treatments such as magnesium sulfate or heliox may be considered to avoid intubation, but intubation should not be delayed once it is deemed necessary (Evidence B). Because intubation of a severely ill asthma patient is difficult and associated with complications, additional treatments are sometimes attempted.
The Expert Panel recommends the following actions regarding intubation:
PATIENT DISCHARGEThe Expert Panel recommends that clinicians, before patients' discharge from the ED or hospital, provide patients with necessary medications and education on how to use them, a referral for a followup appointment, and instruction in an ED asthma discharge plan for recognizing and managing relapse of the exacerbation or recurrence of airflow obstruction (Evidence B). The Expert Panel recommends the following actions for discharging patients from the ED:
Figure 5-7EMERGENCY DEPARTMENT – ASTHMA DISCHARGE PLAN Source: Camargo CA Jr, Emond SD, Boulet L, Gibson PG, Kolbe J, Wagner CW, Brenner BE. Emergency Department Asthma Action Plan. Developed at "Asthma Education in the Adult Emergency Department: A Multidisciplinary (more...) The Expert Panel recommends the following actions for discharging patients from the hospital:
Figure 5-7bEMERGENCY DEPARTMENT – ASTHMA DISCHARGE PLAN : HOW TO USE YOUR METERED - DOSE INHALER Figure 5-8CHECK LIST FOR HOSPITAL DISCHARGE OF PATIENTS WHO HAVE ASTHMA References
What are the adverse effects of albuterol select all that apply?Side effects of albuterol include nervousness or shakiness, headache, throat or nasal irritation, and muscle aches. More-serious — though less common — side effects include a rapid heart rate (tachycardia) or feelings of fluttering or a pounding heart (palpitations).
Which assessment finding by the nurse indicates a common adverse effect of a patient prescribed albuterol inhaler?Common adverse effects of treatment with inhaled albuterol include palpitations, chest pain, rapid heart rate, tremor, and nervousness.
What does albuterol do for asthma?Descriptions. Albuterol is used to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases. It is also used to prevent bronchospasm caused by exercise. Albuterol belongs to the family of medicines known as adrenergic bronchodilators.
What does albuterol do to your lungs?Albuterol is in a class of medications called bronchodilators. It works by relaxing and opening air passages to the lungs to make breathing easier.
|